• Home >
  • Publications >
  • Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

1 Sept 2021Annals of Oncology

DOI : 10.1016/j.annonc.2021.06.002

Authors

A. Bardia, S.M. Tolaney, K. Punie, D. Loirat, M. Oliveira, K. Kalinsky, A. Zelnak, P. Aftimos, F. Dalenc, S. Sardesai, E. Hamilton, P. Sharma, S. Recalde, E.C. Gil, T. Traina, J. O’Shaughnessy, J. Cortes, M. Tsai, L. Vahdat, V. Diéras, L.A. Carey, H.S. Rugo, D.M. Goldenberg, Q. Hong, M. Olivo, L.M. Itri, S.A. Hurvitz